Takahiro Ebata

Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation

Ryota Kurimoto, Shunichiro Iwasawa, Takahiro Ebata et al. · International Journal of Oncology · 2016 · 69 citations · Full text

Tgf-β/fgf-2-driven Epithelial-to-mesenchymal Transition, Immunology, Immunoediting +22

Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma

Ryota Kurimoto, Takahiro Ebata, Shunichiro Iwasawa et al. · Oncology Letters · 2017 · 38 citations · Full text

Substrate Stiffness Influences Doxorubicin-Induced p53 Activation via ROCK2 Expression

Takahiro Ebata, Y Mitsui, Wataru Sugimoto et al. · BioMed Research International · 2017 · 34 citations · Full text

Ecm Rigidity, Oncology, Medicine +15

Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor

Takahiro Ebata, Tatsunori Shimoi, Seiko Bun et al. · Oncology · 2018 · 32 citations

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours

Takahiro Ebata, Toshio Shimizu, Yutaka Fujiwara et al. · Investigational New Drugs · 2019 · 32 citations · Full text